p53 is the most frequently altered tumor suppressor gene in a wide spectrum of human tumors. The large majority of p53 mutations observed in tumors are missense mutations. The p73 gene, encoding a protein with significant sequence similarity to p53, expresses multiple transcription-competent spliced variants, or transcriptionincompetent forms (i.e. DNp73). It was clearly shown that p73 transactivation from a p53-responsive promoter is inhibited by some tumor-derived p53 mutants in eucaryotic cells. In this study, we adapted a yeast-based p53 functional assay for the analysis of the influences of different p53 mutants on the activity of one of the p73 isoforms, namely p73b. We determined the ability of a panel of 61 p53 mutants to inhibit p73b activity following the net transcription of the ADE2 color (red/white) reporter gene driven by a p53-responsive promoter. By analysing a large number of mutants, we could conclude that interference: (a) is a quite frequent phenomenon (more than 70% of p53 mutants analysed are interfering); (b) is not confined to p53 mutations located in particular topological regions of the DNA binding domain; (c) does not appear to be dependent on the kind of side chains introduced at a specific position; (d) appears to significantly correlate with evolutionary conservation of the mutated p53 codon, frequency of occurrence of the mutation in tumors. The influence of a common R/P polymorphism at codon 72 on the ability of p53 mutants to interfere with p73b was also studied. Two sets of polymorphic variants (R and P) for 14 mutants were constructed and analysed. In all cases, the R/P 72 polymorphism was phenotypically irrelevant. In conclusion, our results suggest that the interpretation of the biological effects of p53 mutants should take into consideration the possibility that p53 mutants show loss or gain of function also through the interference with p53 family members.
Introduction
The p53 protein plays a major role in the cellular response to DNA damage, providing a protective effect against tumorigenesis. It integrates signals from the cell's internal or external environment to respond to inappropriate growth-promoting or growth-inhibiting conditions. p53 explicits a plethora of biochemical and biological functions (Ko and Prives, 1996; Levine, 1997; Prives and Hall, 1999; Vogelstein et al., 2000) and acts mainly as tetrameric (dimer of dimers) transcription factor controlling the expression of a number of effector genes. p53 interacts with a specific DNA sequence (consensus 5 0 RRRCWWGYYY3 0 for a dimer) through its DNA binding domain and contacts different elements of the RNApolII transcriptional machinery via its N-terminal acidic transactivation domain. After genotoxic stresses (DNA damaging treatment, hypoxia, redox stress) or oncogenic stimuli (Giaccia and Kastan, 1998) , p53 becomes the target of a number of posttranslational modifications (e.g. phosphorylations at the N-and C-ter domains, acetylations mainly at the C-ter) that cause (1) the weakening of the MDM2::p53 interaction, (2) its activation as transcription factor, and (3) the accumulation of the protein in the nucleus. Several downstream p53 target genes have been identified. Some of them play an important role in the cell cycle control, mainly inducing arrest at the G1/S checkpoint, but also in G2 in the presence of DNA damage (e.g. p21, GADD45, cyclinG). Others are involved in the induction of apoptosis (e.g. BAX, IGF-BP3, PIG3, AIP1, PUMA, FAS, APAF-1), or negatively regulate p53 stability/activity (MDM2).
p53 is the most frequently altered tumor suppressor gene in a wide spectrum of human tumors (Ko and Prives, 1996; Olivier et al., 2002) . The large majority of p53 mutations observed in tumors are missense mutations. The selection for expressed mutant proteins has been explained either considering a dominant-negative effect of mutants over wild type in heterozygosity or by implying that mutant proteins exhibit novel functional properties that can confer a selective growth advantage (gain of function). Mutants have generally lost DNA binding and transactivation capabilities. However, mounting evidence indicates that some mutants are capable of binding DNA, implying that mutants have the capacity to modulate gene expression (Crook et al., 1994; Ludwig et al., 1996; Rowan et al., 1996; Campomenosi et al., 2001) .
Recently, new genes whose products show significant sequence similarity to p53 have been identified: p73 (Kaghad et al., 1997) and p63 (Yang et al., 1998) (reviewed in Kaelin, 1999a; Melino et al., 2002) . The p73 gene expresses multiple transcription-competent variants, encoded by alternatively spliced transcripts (Jost et al., 1997; Kaghad et al., 1997; Kaelin, 1999a) , or transcription-incompetent forms (i.e. DNp73) (Kaelin, 1999a; Melino et al., 2002) . The various isoforms of p73 display a modular structure with extensive homology to p53 within their DNA binding domains (63%), the amino-terminal transcriptional transactivation domain (29%), and the tetramerization domain (38%). It is therefore not surprising that p73 can activate transcription of endogenous p53-responsive genes such as the cell cycle inhibitor p21 (Jost et al., 1997; Kaghad et al., 1997) , or of reporters containing various p53-responsive promoters in mammalian cells or in yeast (Di Como et al., 1999) . However, significant differences were observed between p53 and p73 as far as the relative abilities of each single protein (or isoform) to transactivate were concerned. Therefore, the existence of these new proteins adds new complexity to our understanding of the p53 pathways, since members of the p53 family could, in principle, cooperate, interfere or compete with each other for the access and the activation of p53 effector genes. The partial overlap between p53 and p73 is extended also to their inducers, since both are activated by (different) DNA damaging agents (Agami et al., 1999; Gong et al., 1999; Yuan et al., 1999) .
The significant degree of homology between the tetramerization domain of p53 and p73 suggested that these proteins may forms heterotetramers. Indeed, Kaghad et al. (1997) have shown that p73b, but not p73a, can interact with p53 in a yeast two-hybrid assay. Davison et al. (1999) showed that p73 and p63 form homotetramers capable of weak heterotypic interactions with each other but not with p53. Furthermore, it was clearly shown that a few tumor-derived p53 mutants inhibited p73 transactivation from a p53-responsive promoter in eucaryotic cells (Di Como et al., 1999; Gaiddon et al., 2001) . In this study, we evaluated whether the inhibition of p73b is a common feature of a p53 mutants. This is a very critical issue, view that p73 mutations are extremely rare in tumors (Kaelin, 1999b; Melino et al., 2002) , p53 mutations are instead common and it is therefore possible that the coexistence of wild-type p73 and mutant p53 s occurs quite frequently. Since both p53 and p73 have been shown to act as transcription factors in yeast, we adapted a yeast-based p53 functional assay for the analysis of the influences of different p53 mutants on p73b transactivation. For this purpose, yeast strains carrying the ADE2 reporter gene under the control of different p53-responsive promoter elements (3 Â RGC, yIG397; 1 Â p21: YPH-p21; 1 Â bax: YPH-bax) were used. We first examined the ability of p73b to transactivate the ADE2 gene in different strains. Then we determined the ability of a panel of 61 p53 mutants (Inga et al., 1997b (Inga et al., , 1998 Kelly et al., 1999; Monti et al., 2000; Tada et al., 2001) to inhibit p73b transcription in yIG397. Finally, the influence of a common R/P polymorphism at codon 72 on the ability of p53 mutants to interact with p73b was also studied.
Results

Comparison of p53 and p73b transactivation capability in yeast
To analyse the transactivation potential of p73b for p53 target genes, a CEN-based yeast expression plasmid encoding for p73b was transfected into yeast strains having the ADE2 color (red/white) reporter gene under the control of p53-responsive promoter elements (p21, bax, and 3 Â RGC). As shown in Table 1, p53 transactivates all three reporters, while p73b partially activates the ADE2 reporter only from 3 Â RGC, leading to white/pink colonies. In yeast, p73b appears as a weaker transcription factor compared to p53.
Many p53 mutants inhibit p73b transactivation from the 3 Â RGC p53-responsive element in yeast Interactions between members of the p53 family have been first studied using the two-hybrid system. p73a showed a very low tendency to form homotypic interaction in this assay, while p73b displayed strong homotypic interactions, equivalent to that of p53 (Kaghad et al., 1997) . p53 and p73b displayed significant mutual interactions, while p73a showed minimal interaction with p53. The ability of a few p53 mutants to inhibit p73 transactivation capability was reported by some authors (Di Como et al., 1999; Gaiddon et al., 2001) . These results raise the question of how many of (Inga et al., 1997a) . p53 mutant is constitutively expressed from a LEU2 vector (pLS76) while wild-type p73b is expressed from an otherwise identical TRP1 vector, and net transcriptional activity is scored using the ADEbased reporter under the control of a p53-responsive promoter (Figure 1 ). Double transformant colonies (Leu+Trp+) on selective plates containing limiting adenine, whose color was darker (light pink or pink) than that of the clone coexpressing p73b and wild-type p53 (white), were classified as carrying a mutant able to inhibit p73 transactivation capability (interfering mutant). The analysis of interference was performed only in the yIG397 strain, where clones expressing only p73b originate white/pink colonies (Table 1) .
A panel of 61 p53 mutants obtained in previous studies (Inga et al., 1997b (Inga et al., , 1998 Kelly et al., 1999; Monti et al., 2000; Campomenosi et al., 2001; Tada et al., 2001 ) was used to validate the p73 interference assay (Tables 2 and 3 ). This panel included four mutants (Ser99Phe, Ser99Tyr, Ser314Phe, Arg337Ser) whose amino acid substitutions were located outside the crystallized portion of the p53 core protein (Cho et al., 1994) , one truncated protein (Leu201stop) and 56 mutants localized in different domains of the protein.
Of the 61 mutants, 25 were previously characterized in human tumours of different origin or found in BRCA-associated human cancers (generous gift of Dr T Crook). For each mutant analysed, the following information are indicated in Tables 2 and 3 : (a) if obtained from human tumors; (b) the amino acid at codon 72; (c) the structural element where the residue involved in the mutation is located (nomenclature according to Cho et al., 1994) , (d) its evolution constrain (Soussi and May, 1996) , (e) whether the codon is a hot spot in human cancer (see Materials and methods for definition), (f) the frequency of identical mutations observed in human cancers over the total number of mutations observed at the same codon (IARC database, Olivier et al., 2002 : R7 September release >17 689 mutations, 14 038 of which are missense mutations, silent mutations were not considered), and (g) the color of the yIG397 yeast colonies expressing the mutant alone.
The results of interference analysis of p53 mutants at codons where a single amino acid substitution was analysed (26 mutants) or of mutants at codons where two or three amino acid substitutions were analysed (35 mutants) are reported in Tables 2 and 3 , respectively. At least 53% (14/26) of p53 mutants at codons where a single amino acid substitution was analysed showed the ability to interfere with p73b transactivation function in yIG397 (Table 2) . If the four tumor-derived mutants (T 150 I, G 199 R, R 202 S, S 215 C) that were transcription competent in yIG397 (white colonies) are excluded, the percentage of interfering mutant is even higher (63%, 14/22). We then tested 35 additional p53 mutations at 15 codons, that is, for each codon two or three amino acid substitutions were analysed (Table 3) . In every case, mutants with different amino acid substitutions at the same codon showed identical capacity to interfere with p73b, that is, if one amino acid substitution was interfering the other(s) was (were) also interfering. Our results suggest that, in general, the location more than the amino acid substitution determines the ability of a mutant to be interfering. Among this second group of mutants, 83% (29/35) showed the ability to interfere with p73b transactivation in yIG397 (Table 3) . Altogether (Tables 2 and 3 ), more than 70% of p53 mutants (43/61) were p73b interfering. An example of the interference analysis with three mutants is shown in Figure 2 . When expressed alone in yIG397, each of the mutants (left plate, no 2: H 115 Y; no 3: R 282 W, no 4: G 245 S) clearly appear transactivation defective (red colonies) compared to wild-type p53 (left plate no 1: white colonies). Instead, the mutants appear Figure 1 Schematic representation of the analysis of p53 mutants' ability to interfere with p73b transactivation. The analysis is performed using p53 mutants (expressed by LEU2 vector) unable to transactivate the reporter gene and in yIG397 where p73b (expressed by a TRP vector) is at least partially transcriptionally competent (i.e. generates white/pink colonies). Double transformants (Trp+ Leu+) expressing a not-interfering p53 mutant or an interfering mutant originate white/white pink colonies (1) Table 2 ), very interfering (R 282 W, 'yes+', in Table 3 ), and interfering (G 245 S, 'yes', in Table 3 ). It is known that p53 mutants may be classified as dominant or recessive, if they (partially) abrogate wildtype p53 transactivation functions. A total of 37 p53 mutants among our panel were already characterized using a yeast-based assay for dominance (Inga et al., 1997a; Monti et al., 2002) . The remaining 24 mutants were characterized in the present study (see Tables 2 and  3 , results underlined). Excluding the four transactivation competent mutants (T 150 I, G 199 R, R 202 S, S 215 C), which were obviously recessive, 18 mutants out of 57 (32%) were classified as dominant (Tables 2 and 3) .
Influence of R/P 72 polymorphism on the ability of p53 mutants to interfere with p73b activity It has been postulated that a common R/P polymorphism at codon 72 of p53 may influence the ability of the mutants to form heterotypic interactions with p63 and p73. However, all the reports published so far are not always consistent (Marin et al., 2000; Tada et al., 2001; Gaiddon et al., 2001) . Of the 25 mutants present in our panel of mutants isolated in human tumors, 20 mutants present an R (arginine) at codon 72 (Tables 2 and 3) . However, there are examples of mutants with different amino acid changes at the same codon (158, 173, 181, 219, 273) that also differ at the R/P 72 polymorphic site (e.g. R 158 C (72P) vs R 158 G (72R)) and that showed exactly the same ability/inability to interfere with p73b (Table 3) . Since in general the location more than the amino acid substitution determines the ability of a mutant to be interfering (see above), this observation suggests the hypothesis, that the R/P polymorphism at codon 72 did not influence the result. In order to verify this hypothesis, the R and P polymorphic variants of 14 mutants were constructed and analysed (Table 4) . In all Soussi and May, 1996) . .
j Found in BRCA-associated human cancers (generous gift of Dr T Crook).
k Not yet present in the IARC database but already published in Tada et al. (2001) p53 mutants inhibit p73b P Monti et al cases, the R/P 72 polymorphism did not influence the extent of wild-type p73b or p53 inhibition (or lack thereof) by the p53 mutants. In fact, the two polymorphic variants of each mutant showed the same: (a) ability/inability to transactivate the ADE2 gene in yIG397; (b) dominant/recessive potential vs wild-type p53; (c) ability to interfere with p73b. We conclude that the amino acid present at position 72 does not influence protein::protein interaction (p53 mut::p53WT; p53 mut::p73bWT) in this experimental system.
Discussion
Using yeast as a model system to study functional interference of p53 mutants with a specific p73 isoform, namely p73b, we first confirmed that p73b per se is a weaker transactivation factor compared to p53. In fact, unlike wild-type p53, p73b failed to activate a promoter containing the BAX and the p21-responsive elements in the experimental condition adopted in this study. However, it has to be pointed out that since the transactivation analysis was performed in nonisogenic conditions (only the bax and the p21 strains are isogenic) and only at moderate expression of p73b, our results cannot be taken as conclusive evidence that p73b is not active towards a subset of p53-responsive elements in yeast. Further analysis in a more controlled system is warranted to explore the broad issue of relative transactivation capacity of p73 isoforms. We then demonstrated that a large fraction of the mutants analysed (more than 70% of p53 mutants) is able to interfere with p73b. This suggests that if coexpressed in Soussi and May, 1996) . d Hot spot codon for mutation (yes), cold spot (no); (for definition see Materials and methods).
e Based on the September 2002 release of the IARC database (Olivier et al., 2002) , excluding silent mutations.
f Phenotype of yIG397 colonies expressing the p53 mutant alone. Note that some p53 mutants found in BRCA-associated tumour are phenotypically indistinguishable from wild type.
g Mutant p53 coexpressed with wild-type p73b generating light pink, dark pink or white/white pink Leu+Trp+ colonies in yIG397 strain (3 Â RGC) were classified as interfering (yes), very interfering (yes+) or not interfering (no), respectively. h Mutant classified as r (recessive) or D (dominant), respectively. Underlined are the results obtained in the present study, the remainig are from Monti et al. (2002) .
i Found in human tumors . j Found in BRCA-associated human cancers (generous gift of Dr T Crook)
p53 mutants inhibit p73b P Monti et al a tumor cell, a mutant p53 has a high probability to interfere with the p73 pathway. Which are the features of the p53 mutants able to interfere with p73b? It appears that amino acid substitutions in mutants able to mediate the interference with p73b involve residues with higher evolutionary conservation than those unable to interfere with p73b (w 2 test, Po0.04), more often classified as hot spots than cold spots (Fisher's exact test, Po0.01). Interestingly, all 18 mutants that were classified as dominant (Tables 2  and 3) were also able to interfere with p73b. All these features appear to be independent of the polymorphism at codon 72. In other words, by analysing a large number of mutants, we could conclude that interference: (a) is a quite frequent phenomenon (more than 70% of p53 mutants analysed are interfering); (b) is not confined to p53 mutations located in particular topological regions of the DNA binding domain; (c) does not appear to be dependent on the kind of side chains introduced at a specific position; (d) appears to significantly correlate with evolutionary conservation of the mutated p53 codon, frequency of occurrence of the mutation in tumors irrespective of the nature of the amino acid at codon 72. Furthermore, while mutants characterized as dominant vs wild-type p53 have high probability to also be able to interfere with p73b, recessive mutants can be classified as interfering or noninterfering mutants.
How mutant p53 and wild-type p73b do interact? Gaiddon et al. (2001) suggested that the mechanisms by which p53 mutants affect p73 is most likely because of a direct interaction between the two proteins rather then competition by p53 proteins for the same responsive element. They showed that a subset of tumor-derived mutant forms of p53 downregulate p73 (and p63) Figure 2 Phenotype of p53 mutants expressed alone in yIG397 (left) and analysis of interference of the indicated mutants when coexpressed with p73b (right). Left plate: color of yeast colonies expressing: wild-type p53 (white colonies) (1), or mutants: H115Y (2), R282W (3) and G245S (4) (red colonies). Right plate: color of double transformant colonies coexpressing p73b and wild-type p53 (1) or mutants H115Y (2), R282W (3) and G245S (4) Table 4 Ability of p53 mutants to interfere with wild-type p73b (yes or no) or with p53 (being classified as recessive: r; Dominant: D) in the yIG397 strain (3 Â RGC). Effects of the 72R/P polymorphism with the same amino acid substitutions at the same codon
Amino acid at codon 72. b Phenotype of yIG397 colonies expressing the p53 mutant alone.
c Mutant p53 coexpressed with wild-type p73b generating light pink/pink or white/white pink Leu+Trp+ colonies in yIG397 strain (3 Â RGC) were classified as interfering (yes), or not interfering (no), respectively.
d Mutant p53 classified as r (recessive) or D (dominant), respectively. Underlined are the results obtained in the present study, the remainig are from Monti et al. (2002) p53 mutants inhibit p73b P Monti et al through a direct interaction with the p53 core domain. In the present work, we did not perform protein::protein interaction studies. Nevertheless, the net transcription of the ADE2 gene indicates a functional interference of p53 mutants towards p73b. The residues at amino acid substitutions that are p73 interfering are not randomly distributed along the p53 protein. Indeed, of the 60 mutants with single amino-acid substitutions (one has a nonsense mutation), 56 are localized in the crystallized portion of the core of p53 (four are located outside this portion) and 35 are occurring in protein domains involved in DNA::protein interaction (L1-S2/S2 0 -L2, H1, L3, S10-H2) (nomenclature according to Cho et al., 1994) . The incidence of interfering mutants in this group of mutants is significantly higher (Po0.05, Fisher's exact test) than in the group of mutants occurring far away from the protein::DNA interaction surface. In other words, interfering mutants appear to be mainly located in the region/surface of protein::DNA interaction.
The fact that all dominant mutants studied are also interfering p73b transactivation capability is intriguing. Indeed, besides the fact that interactions between p53 mutant::p53 wild type and between p53 mutant::p73b are thought to be mediated by different protein domains (the former via the tetramerization domain of p53, the latter via core domain of p53), the functional consequences of both interactions are similar (downregulation of transactivation capability of the wild-type partner (p53 or p73b, respectively). We showed that tumor p53 mutations exhibit promoter selective dominance over wild-type p53 (Monti et al., 2002) . Since very recently it has been shown that p73(a) and p53 activates both common and distinct groups of genes (Fontemaggi et al., 2002) , it is possible that the ability of a p53 mutant to interfere with p73 family members may be stronger for specific p53-responsive elements. Studies testing this hypothesis are warranted.
The interaction with and the downregulation of p73 by p53 mutants might contribute to tumorigenesis. The role of p73 in malignancy is a complicated issue (Stiewe and Pu¨tzer, 2002) . However, the cooperation between p53 family members at least in inducing apoptosis was demonstrated (Flores et al., 2002) . Indeed, p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Although the tissue and stage-specific expression pattern of p73 would imply that only certain tumors would express both p53 mutant and p73, many types of tumors overexpress wild-type p73 (or the DNp73) (Zaika et al., 2002) . It is possible that the ability of tumors to tolerate high levels of p73 is associated in some cases to the presence of interfering p53 mutants. Marin et al. (2000) proposed that interaction of mutant p53 with p73 might play a role in the establishment of squamous cell cancers. In their study, two factors conditioned the ability of p53 mutants to interact with p73: (a) the type of missense mutation and (b) the presence of a specific polymorphic variant (R vs P) at codon 72. Recently Tada et al. (2001) found that there is a preferential selection of R72 alleles in cancers with recessive p53 mutants while, in presence of transdominant mutants, such preferential selection did not occur. These authors interpreted the R72 bias with recessive mutants as evidence that decreased activation of p53 target genes provides a selective growth advantage to tumor cells during the stage of tumorigenesis in which a wild-type and mutant p53 allele coexist. They also suggested that transdominant p53 mutants achieve this by inactivation of the remaining wild-type allele, whereas recessive p53 mutants achieve it through inactivation of p73. We directly tested this hypothesis by constructing two sets of p53 mutant alleles differing only by the amino acid present at codon 72. We showed that for all mutants tested, the polymorphic variants of the same mutant allele showed no difference in terms of transdominant potential and of ability to interfere with p73b (Table 4) . Therefore, although appealing, the model proposed by Tada et al. (2001) is not supported by the results obtained in this experimental system. In line with our results are instead those obtained by Gaiddon et al. (2001) , who found that of the three best p73 interacting p53 mutants, two were P72 variants.
The present work was performed only in yeast cells. The yeast assay allows to test the functional interaction in a constant environment without the complication of multiple spliced or alternative-promoter variants. Four p53 mutants (P 151 S, V 173 L, R 248 W, R 273 H) have been tested in our study for interference and independently by Gaiddon et al. (2001) in mammalian cells for physical interaction with p73. Interestingly all of them were interfering mutants in yeast and were able to bind strongly to p73 in mammalian cells.
In conclusion, our results strongly suggest that the interpretation of the biological effects of p53 mutants should take into consideration the possibility that p53 mutants show loss or gain of function also through the interference with p53 family members.
Materials and methods
Strains, vectors, and media
Saccharomyces cerevisiae haploid p53-reporter strains, yIG397 (3 Â RGC::pCYC1::ADE2) (Inga et al., 1997b) , YPH-p21 and YPH-bax (Flaman et al., 1998) , were transformed with pLS76 yeast expression vector (CEN6/ARS4, LEU2) coding for the human wild-type (or mutated) p53 cDNA under an ADH1 promoter. Transformants were selected on synthetic minimal medium (Difco, Milano, Italy) lacking leucine, but containing a limiting amount of adenine (5 mg/l). The expression of wildtype p53 conferred adenine prototrophy (white, normal size colonies), while the expression of a mutant p53 unable to transactivate the ADE2 gene conferred adenine auxotrophy (small red colonies). The 61 mutant (pLS76) plasmids tested were obtained in different studies using the yeast functional assay as mutagenesis tool (Inga et al., 1997b (Inga et al., , 1998 Kelly et al., 1999; Monti et al., 2000; Campomenosi et al., 2001) or through the characterization of the p53 status in human tumors and a generous gift of Dr Tim Crook). 
Construction of the p73b expression vector
Plasmid pMT9, harboring the p73b cDNA under the ADH1 promoter, was previously constructed (Nozaki et al., 2001) . The plasmid also contains a CEN/ARS cassette, a LEU2 selectable marker, b-lactamase gene (AmpR) and a bacterial Ori of replication. In order to study whether p53 mutants expressed by pLS76 plasmids (LEU2) interfere with p73b, a new CEN/ARS ADH1-p73 expression vector having a TRP1-selectable marker was constructed by ligating a PvuI fragment (bp 2454-6556) from pMT9 containing the pADH1-p73b cDNA to a PvuI fragment (bp 6732-1736) from pTS76 (Inga et al., 1997a) containing the TRP1 gene. The resulting product, named p73bT, is identical to pMT9 except for the TRP1 marker that replaces LEU2. The expression plasmids containing either the TRP1 or the LEU2 marker were separately used and the results were 'selectable marker' independent.
Analysis of the promoter discrimination properties of p73b
In order to analyse whether p73b was able to transactivate the ADE2 gene under the control of different p53-responsive elements, the p73bT plasmid was transformed into the different yeast strains (yIG397, YPH-p21, YPH-bax) by the LiAc method. Transformants were selected on appropriate plates incubated for 3 days at 301C.
Construction of the R/P72 polymorphic variants
For 14 mutants, two distinct sets of alleles (R and P) were constructed and analysed. Originally, all mutants had a proline at the polymorphic codon 72 (P72). The corresponding set of mutants with arginine at codon 72 was prepared by digesting the pLS76 plasmids carrying the appropriate mutants with SgrAI and StuI restriction endonucleases. These enzymes cut the plasmid in the p53 coding sequence downstream of codon 72. The purified inserts were cloned into the same sites of a pLS76 recipient plasmid carrying arginine at codon 72 of the p53 gene (R72). All new constructs were checked by DNA sequencing.
Evaluation of p53 mutants ability to interfere with p73b transactivation capability
In order to verify whether p53 mutants inhibit p73b transactivation function, we adapted the yeast-based p53 functional assay we previously developed to classify p53 mutants according to their dominant potential (Inga et al., 1997b) . The p53 mutants and the p73b wild-type proteins are expressed from a moderate promoter (pADH1) in order to avoid protein overexpression. Every p53 mutant is constitutively expressed from a LEU2 vector (pLS76), while the wildtype p73b is expressed from an otherwise identical TRP1 vector and net transcriptional activity is scored using the ADE2-based reporter under the control of different p53-responsive promoters. Double transformant colonies (Leu+Trp+) whose color was darker (light pink/pink or pink/red) than that of the clone coexpressing wild-type p53 and p73b on plates containing limiting adenine were classified as expressing a p53 mutant able to inhibit p73 transactivation capability.
Definition of hot spot for mutation in human tumors
In the last release of the IARC database, there are 17 689 somatic mutations, 14 038 of which are missense mutations (silent mutations were excluded) and occurs at 316 codons. Assuming a Poisson's distribution, codons with more that 57 mutations/site can be defined as hot spot (Po0.05).
